ProQR Ebitda vs Gross Profit Analysis

PRQR Stock

USD 3.84 0.17 4.63%

ProQR Therapeutics financial indicator trend analysis is much more than just breaking down ProQR Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ProQR Therapeutics is a good investment. Please check the relationship between ProQR Therapeutics Ebitda and its Gross Profit accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

Ebitda vs Gross Profit

Ebitda vs Gross Profit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ProQR Therapeutics Ebitda account and Gross Profit. At this time, the significance of the direction appears to have almost no relationship.

The correlation between ProQR Therapeutics' Ebitda and Gross Profit is 0.19. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Gross Profit in the same time period over historical financial statements of ProQR Therapeutics BV, assuming nothing else is changed. The correlation between historical values of ProQR Therapeutics' Ebitda and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of ProQR Therapeutics BV are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Ebitda i.e., ProQR Therapeutics' Ebitda and Gross Profit go up and down completely randomly.

Correlation Coefficient

0.19

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Ebitda

Gross Profit

Gross profit is a required income statement account that reflects total revenue of ProQR Therapeutics BV minus its cost of goods sold. It is profit before ProQR Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most indicators from ProQR Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ProQR Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

As of 11/29/2024, Selling General Administrative is likely to drop to about 12.6 M. In addition to that, Tax Provision is likely to grow to about (74.1 K)

ProQR Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Property Plant And Equipment Gross
Total Assets		0.78	0.89	0.71	0.84	0.49	-0.9	-0.78	0.27	0.96	0.72	0.68	0.96	0.38	0.86	0.81	0.76	0.68	0.92	0.77	1.0	0.81	0.84	0.7	0.41	0.68
Short Long Term Debt Total	0.78		0.85	0.62	0.57	0.3	-0.58	-0.7	-0.1	0.76	0.75	0.9	0.76	0.13	0.73	0.73	0.68	0.47	0.77	0.68	0.75	0.66	0.5	0.74	0.27	0.65
Other Current Liab	0.89	0.85		0.74	0.67	0.44	-0.74	-0.83	0.06	0.85	0.73	0.76	0.85	0.31	0.89	0.86	0.75	0.73	0.92	0.76	0.88	0.82	0.62	0.72	0.39	0.68
Total Current Liabilities	0.71	0.62	0.74		0.38	0.87	-0.65	-0.93	0.56	0.66	0.86	0.39	0.66	0.23	0.69	0.84	0.9	0.51	0.8	0.95	0.69	0.95	0.45	0.86	0.9	0.93
Total Stockholder Equity	0.84	0.57	0.67	0.38		0.1	-0.92	-0.42	0.24	0.91	0.34	0.61	0.91	0.09	0.66	0.41	0.35	0.55	0.63	0.36	0.87	0.52	0.97	0.33	0.11	0.27
Other Liab	0.49	0.3	0.44	0.87	0.1		-0.39	-0.84	0.61	0.35	0.78	-0.03	0.35	0.47	0.49	0.72	0.86	0.26	0.63	0.88	0.45	0.84	0.21	0.78	0.92	0.9
Net Debt	-0.9	-0.58	-0.74	-0.65	-0.92	-0.39		0.61	-0.48	-0.96	-0.49	-0.54	-0.96	-0.09	-0.73	-0.59	-0.54	-0.59	-0.75	-0.58	-0.92	-0.72	-0.96	-0.48	-0.45	-0.49
Retained Earnings	-0.78	-0.7	-0.83	-0.93	-0.42	-0.84	0.61		-0.36	-0.67	-0.92	-0.44	-0.67	-0.42	-0.85	-0.93	-0.93	-0.48	-0.92	-0.95	-0.74	-0.98	-0.44	-0.91	-0.75	-0.93
Accounts Payable	0.27	-0.1	0.06	0.56	0.24	0.61	-0.48	-0.36		0.32	0.31	-0.22	0.32	-0.08	0.21	0.28	0.32	0.07	0.24	0.4	0.28	0.49	0.43	0.31	0.73	0.42
Cash	0.96	0.76	0.85	0.66	0.91	0.35	-0.96	-0.67	0.32		0.6	0.73	1.0	0.13	0.82	0.7	0.61	0.63	0.84	0.64	0.97	0.73	0.92	0.59	0.37	0.56
Non Current Assets Total	0.72	0.75	0.73	0.86	0.34	0.78	-0.49	-0.92	0.31	0.6		0.51	0.6	0.36	0.73	0.86	0.92	0.34	0.82	0.92	0.66	0.88	0.37	1.0	0.68	0.96
Long Term Debt	0.68	0.9	0.76	0.39	0.61	-0.03	-0.54	-0.44	-0.22	0.73	0.51		0.73	-0.08	0.58	0.5	0.43	0.52	0.59	0.43	0.67	0.41	0.51	0.5	0.01	0.39
Cash And Short Term Investments	0.96	0.76	0.85	0.66	0.91	0.35	-0.96	-0.67	0.32	1.0	0.6	0.73		0.13	0.82	0.7	0.61	0.63	0.84	0.64	0.97	0.73	0.92	0.59	0.37	0.56
Net Receivables	0.38	0.13	0.31	0.23	0.09	0.47	-0.09	-0.42	-0.08	0.13	0.36	-0.08	0.13		0.31	0.45	0.57	0.4	0.43	0.48	0.37	0.36	0.05	0.35	0.1	0.4
Common Stock Total Equity	0.86	0.73	0.89	0.69	0.66	0.49	-0.73	-0.85	0.21	0.82	0.73	0.58	0.82	0.31		0.89	0.69	0.5	0.97	0.7	0.84	0.84	0.66	0.72	0.41	0.65
Common Stock Shares Outstanding	0.81	0.73	0.86	0.84	0.41	0.72	-0.59	-0.93	0.28	0.7	0.86	0.5	0.7	0.45	0.89		0.88	0.5	0.95	0.89	0.77	0.89	0.45	0.85	0.61	0.85
Non Current Liabilities Total	0.76	0.68	0.75	0.9	0.35	0.86	-0.54	-0.93	0.32	0.61	0.92	0.43	0.61	0.57	0.69	0.88		0.54	0.84	0.99	0.72	0.9	0.38	0.92	0.72	0.97
Other Current Assets	0.68	0.47	0.73	0.51	0.55	0.26	-0.59	-0.48	0.07	0.63	0.34	0.52	0.63	0.4	0.5	0.5	0.54		0.57	0.54	0.7	0.51	0.49	0.32	0.2	0.38
Other Stockholder Equity	0.92	0.77	0.92	0.8	0.63	0.63	-0.75	-0.92	0.24	0.84	0.82	0.59	0.84	0.43	0.97	0.95	0.84	0.57		0.84	0.89	0.91	0.64	0.81	0.52	0.78
Total Liab	0.77	0.68	0.76	0.95	0.36	0.88	-0.58	-0.95	0.4	0.64	0.92	0.43	0.64	0.48	0.7	0.89	0.99	0.54	0.84		0.73	0.94	0.4	0.92	0.79	0.98
Total Current Assets	1.0	0.75	0.88	0.69	0.87	0.45	-0.92	-0.74	0.28	0.97	0.66	0.67	0.97	0.37	0.84	0.77	0.72	0.7	0.89	0.73		0.79	0.87	0.65	0.38	0.63
Common Stock	0.81	0.66	0.82	0.95	0.52	0.84	-0.72	-0.98	0.49	0.73	0.88	0.41	0.73	0.36	0.84	0.89	0.9	0.51	0.91	0.94	0.79		0.56	0.87	0.8	0.91
Net Tangible Assets	0.84	0.5	0.62	0.45	0.97	0.21	-0.96	-0.44	0.43	0.92	0.37	0.51	0.92	0.05	0.66	0.45	0.38	0.49	0.64	0.4	0.87	0.56		0.36	0.25	0.32
Property Plant And Equipment Net	0.7	0.74	0.72	0.86	0.33	0.78	-0.48	-0.91	0.31	0.59	1.0	0.5	0.59	0.35	0.72	0.85	0.92	0.32	0.81	0.92	0.65	0.87	0.36		0.69	0.96
Current Deferred Revenue	0.41	0.27	0.39	0.9	0.11	0.92	-0.45	-0.75	0.73	0.37	0.68	0.01	0.37	0.1	0.41	0.61	0.72	0.2	0.52	0.79	0.38	0.8	0.25	0.69		0.82
Property Plant And Equipment Gross	0.68	0.65	0.68	0.93	0.27	0.9	-0.49	-0.93	0.42	0.56	0.96	0.39	0.56	0.4	0.65	0.85	0.97	0.38	0.78	0.98	0.63	0.91	0.32	0.96	0.82

Click cells to compare fundamentals

ProQR Therapeutics Account Relationship Matchups

ProQR Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	117.5M	98.7M	209.6M	171.3M	137.9M	108.5M
Short Long Term Debt Total	13.6M	34.3M	60.4M	22.0M	19.7M	18.5M
Other Current Liab	9.0M	7.0M	14.8M	10.1M	8.8M	6.9M
Total Current Liabilities	11.0M	10.3M	27.6M	21.1M	34.2M	35.9M
Total Stockholder Equity	94.3M	57.1M	113.8M	65.5M	41.4M	69.4M
Net Debt	(98.4M)	(41.6M)	(127.2M)	(72.8M)	(99.2M)	(104.2M)
Retained Earnings	(211.7M)	(257.7M)	(317.8M)	(380.7M)	(400.9M)	(380.8M)
Accounts Payable	445K	221K	191K	392K	1.5M	1.6M
Cash	112.0M	75.8M	187.5M	94.8M	118.9M	92.9M
Non Current Assets Total	2.9M	18.7M	18.1M	16.9M	16.9M	17.7M
Long Term Debt	12.7M	16.2M	39.3M	4.3M	4.3M	4.1M
Cash And Short Term Investments	112.0M	75.8M	187.5M	94.8M	118.9M	92.9M
Net Receivables	850K	421K	555K	57.2M	1.3M	1.2M
Common Stock Total Equity	1.5M	1.7M	2.2M	2.2M	2.5M	1.3M
Common Stock Shares Outstanding	41.0M	50.1M	64.2M	71.6M	81.0M	41.6M
Liabilities And Stockholders Equity	117.5M	98.7M	209.6M	171.3M	137.9M	108.5M
Non Current Liabilities Total	12.7M	31.9M	68.8M	85.1M	62.3M	65.4M
Other Current Assets	1.5M	(800K)	3.1M	2.4M	793K	1.2M
Other Stockholder Equity	303.8M	288.8M	398.3M	412.5M	412.9M	236.7M
Total Liab	23.7M	42.2M	96.4M	106.2M	96.5M	101.3M
Total Current Assets	114.7M	80.0M	191.5M	154.5M	121.0M	100.7M
Common Stock	2.2M	2.2M	3.0M	3.4M	3.9M	4.1M
Net Tangible Assets	94.3M	57.1M	113.8M	65.5M	75.3M	82.9M
Property Plant And Equipment Net	2.4M	18.6M	17.5M	16.2M	16.9M	17.7M
Current Deferred Revenue	711K	700K	5.1M	5.8M	20.6M	21.6M
Property Plant And Equipment Gross	3.8M	18.6M	27.8M	29.1M	32.1M	33.7M
Short Long Term Debt	343K	1.1M	4.8M	2.5M	2.3M	2.1M
Accumulated Other Comprehensive Income	151K	(189K)	30.3M	30.3M	26.0M	27.3M
Short Term Debt	851K	2.4M	6.3M	3.9M	1.6M	2.0M
Property Plant Equipment	2.4M	18.6M	17.5M	16.2M	18.7M	19.6M
Capital Lease Obligations	508K	17.0M	16.3M	15.2M	15.4M	16.2M
Inventory	340K	379K	266.5K	6.9K	1.0	0.95
Net Invested Capital	107.4M	74.4M	157.9M	72.3M	45.7M	69.3M
Net Working Capital	103.7M	69.7M	163.9M	133.3M	86.8M	110.0M

Pair Trading with ProQR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with ProQR Stock

0.76	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr
0.76	EWTX	Edgewise Therapeutics	Pair Corr

Moving against ProQR Stock

0.83	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.81	HLN	Haleon plc	Pair Corr
0.77	TAK	Takeda Pharmaceutical	Pair Corr
0.74	ELAN	Elanco Animal Health	Pair Corr
0.67	RDY	Dr Reddys Laboratories	Pair Corr

The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.

The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ProQR Stock Analysis

When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC